KR920018043A - 6-헤테로사이클릭-4-아미노-1,3,4,5-테트라하이드로벤즈[cd]인돌 - Google Patents

6-헤테로사이클릭-4-아미노-1,3,4,5-테트라하이드로벤즈[cd]인돌 Download PDF

Info

Publication number
KR920018043A
KR920018043A KR1019920004936A KR920004936A KR920018043A KR 920018043 A KR920018043 A KR 920018043A KR 1019920004936 A KR1019920004936 A KR 1019920004936A KR 920004936 A KR920004936 A KR 920004936A KR 920018043 A KR920018043 A KR 920018043A
Authority
KR
South Korea
Prior art keywords
indole
propylamino
tetrahydrobenz
alkyl
hydrogen
Prior art date
Application number
KR1019920004936A
Other languages
English (en)
Other versions
KR100221158B1 (ko
Inventor
놀란 부허 리챠드
어니스트 로우혼 데이비드
쥬니어 찰스 죤슨 파겟
메너트 샤우스 죤
Original Assignee
원본미기재
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 일라이 릴리 앤드 캄파니 filed Critical 원본미기재
Publication of KR920018043A publication Critical patent/KR920018043A/ko
Application granted granted Critical
Publication of KR100221158B1 publication Critical patent/KR100221158B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

내용 없음

Description

6-헤테로사이클릭-4-아미노-1,3,4,5-테트라하이드로벤즈[cd]인돌
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (3)

  1. 하기 일반식(1)의 화합물 또는 그의 약학적으로 허용되는 염.
    상기 식에서, R1은 수소, C1-C4알킬, C3-C4알케닐, 사이클로프로필메틸, 페닐-치환된 C1-C4알킬, -(CH2)nS(C1-C4알킬), -C(O)R4또는 -(CH2)nC(O)NR5R6이고, R2는 수소, C1-C4알킬, 사이클로프로피리메틸 또는 C3-C4알케닐이며, R3는 수소, C1-C4알킬 또는 아미노-보호그룹이고, R4는 수소, C1-C4알킬, C1-C4할로알킬, C1-C4알콕시 또는 페닐이며, R5및 R6는 독립적으로 수소, C1-C4알킬 또는 C5-C8사이클로 알킬이지만, 단, R5및 R6중의 하나가 사이클로알킬인 경우 다른 하나는 수소이며, HET는, 동일하거나 상이하며 황, 산소 및 질소로 이루어진 그룹 중에서 선택된 1내지 3개의 헤테로 원자를 갖는 5-원 또는 6-원 방향족 헤테로환상 고리이지만, 단, 6-원 헤테로환상 고리는 단지 탄소 및 질소만을 함유할 수 있고, 또한 5-원 고리는 산소 및 황 둘 모두가 아닌 단 하나의 산소 또는 단 하나의 황만을 함유할 수 있으며, n은 1내지 4이다.
  2. 제 1항에 있어서, (+)(4S)-6-(3-이속사졸릴)-4-(디-n-프로필아미노)-1,3,4,5-테트라하이드로밴즈[cd]인돌;(-)(4R)-6-(5-이속사졸릴)-4-(디-n-프로필아미노)-1,3,4,5-테트라하이드로밴즈[cd]인돌;(±)-6-(3-피라졸릴)-4-(디-n-프로필아미노)-1,3,4,5-테트라하이드로밴즈[cd]인돌;(-)(4R)-6-(4-피라졸릴)-4-(디메틸아미노)-1,3,4,5-테트라하이드로밴즈[cd]인돌;(-)(4R)-6-(4-피리디닐)-4-(디-n-프로필아미노)-1,3,4,5-테트라하이드로밴즈[cd]인돌;(±)-6-(2-피리디닐)-4-(디-n-프로필아미노)-1,3,4,5-테트라하이드로벤즈[cd]인돌;(-)(4R)-6-(2-티아졸릴)-4-(디-n-프로필아미노)-1,3,4,5-테트라하이드로벤즈[cd]인돌;(-)(4R)-6-(5-티아졸릴)-4-(디-n-프로필아미노)-1,3,4,5-테트라하이드로벤즈[cd]인돌;(-)(4R)-6-(3-옥시디아졸릴)-4-(디-n-프로필아미노)-1,3,4,5-테트라하이드로벤즈[cd]인돌;(-)(4R)-6-(3-이속사)-4-디(사이클로프로필메틸)-1,3,4,5-테트라하이드로벤즈[cd]인돌;(-)(4R)-6-(3-이속사졸)-4-(디-n-프로필아미노)-1,3,4,5-테트라하이드로벤즈[cd]인돌;(-)(4R)-6-(3-피라질)-4-(디-n-프로필아미노)-1,3,4,5-테트라하이드로벤즈[cd]인돌;(-)(4R)-6-(2-피라질)-4-(디-n-프로필아미노)-1,3,4,5-테트라하이드로벤즈[cd]인돌(-)(4R)-6-(3-페닐옥사디아졸-5-일)-4-(디-n-프로필아미노)-1,3,4,5,-테트라하이드로벤즈[cd]인돌; 및 (-)(4R)-6-(2-옥사졸릴)-4-(디-n-프로필아미노)-1,3,4,5,-테트라하이드로벤즈[cd]인돌로 이루어진 그룹 중에서 선택된 화합물 또는 그의 약학적으로 허용되는 염.
  3. 활성성분으로서의 제 1항 또는 제 2항에 청구된 화합물 또는 그의 약학적으로 허용되는 염을 하나 이상의 약학적으로 허용되는 담체, 희석제 또는 부형제와 함께 포함하는 약학적 제형.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920004936A 1991-03-28 1992-03-26 6-헤테로사이클릭-4-아미노-1,3,4,5-테트라하이드로벤즈(cd)인돌 KR100221158B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US677,016 1991-03-28
US07/677,016 US5244912A (en) 1991-03-28 1991-03-28 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz(cd)indoles and pharmaceutical use thereof

Publications (2)

Publication Number Publication Date
KR920018043A true KR920018043A (ko) 1992-10-21
KR100221158B1 KR100221158B1 (ko) 1999-09-15

Family

ID=24716969

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920004936A KR100221158B1 (ko) 1991-03-28 1992-03-26 6-헤테로사이클릭-4-아미노-1,3,4,5-테트라하이드로벤즈(cd)인돌

Country Status (26)

Country Link
US (1) US5244912A (ko)
EP (1) EP0506363B1 (ko)
JP (1) JP3159766B2 (ko)
KR (1) KR100221158B1 (ko)
CN (2) CN1059210C (ko)
AT (1) ATE180256T1 (ko)
AU (1) AU649319B2 (ko)
BR (1) BR9201089A (ko)
CA (1) CA2064384A1 (ko)
CS (1) CS85692A3 (ko)
DE (1) DE69229197T2 (ko)
DK (1) DK0506363T3 (ko)
ES (1) ES2133303T3 (ko)
FI (1) FI921347A (ko)
GR (1) GR3030760T3 (ko)
HK (1) HK1013824A1 (ko)
HU (1) HU217590B (ko)
IE (1) IE921001A1 (ko)
IL (1) IL101324A (ko)
MX (1) MX9201374A (ko)
MY (1) MY108450A (ko)
NO (1) NO301642B1 (ko)
NZ (1) NZ242088A (ko)
RU (1) RU2059621C1 (ko)
YU (1) YU31492A (ko)
ZA (1) ZA922070B (ko)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244911A (en) * 1991-03-28 1993-09-14 Eli Lilly And Company 6-heterocyclic-4-amino-1,2,2a,3,4,5-hexahydrobenz(cd)indoles and pharmaceutical use thereof
US5364856A (en) * 1991-03-28 1994-11-15 Eli Lilly And Company 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz[CD]indoles
GB9211277D0 (en) 1992-05-28 1992-07-15 Glaxo Group Inc Pharmaceutical compositions
NZ314570A (en) * 1993-06-10 2000-11-24 Lilly Co Eli Treatment of emesis using tetrahydrobenz[cd]indole-6-carboxamides
US5385928A (en) * 1994-05-18 1995-01-31 Eli Lilly And Company Tetrahydrobenz [CD] indazoles, compositions and use
WO1995032965A1 (fr) * 1994-06-01 1995-12-07 Yamanouchi Pharmaceutical Co. Ltd. Derive de l'oxadiazole et composition medicinale a base de ce dernier
FR2732964B1 (fr) * 1995-04-14 1997-05-16 Adir Nouveaux amides tricycliques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
TW430660B (en) * 1996-05-30 2001-04-21 Mochida Pharm Co Ltd Novel benzindole derivatives for neuron cell protection, processes for production, and the pharmaceutical compounds containing them
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US6479535B1 (en) * 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
WO1999064044A1 (en) * 1998-06-08 1999-12-16 Advanced Medicine, Inc. Novel therapeutic agents that modulate 5-ht receptors
KR102355670B1 (ko) 2013-03-15 2022-02-08 인사이트 홀딩스 코포레이션 Bet 단백질 저해제로서의 삼환식 복소환
CA2917319A1 (en) 2013-07-08 2015-01-15 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
WO2015081189A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
WO2015095492A1 (en) 2013-12-19 2015-06-25 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
UA119870C2 (uk) 2014-04-23 2019-08-27 Інсайт Корпорейшн 1H-ПІРОЛО[2,3-c]ПІРИДИН-7(6H)-ОНИ ТА ПІРАЗОЛО[3,4-c]ПІРИДИН-7(6H)-ОНИ ЯК ІНГІБІТОРИ БІЛКІВ BET
ES2855225T3 (es) 2014-09-15 2021-09-23 Incyte Corp Heterociclos tricíclicos para su uso como inhibidores de proteínas BET
AR106520A1 (es) 2015-10-29 2018-01-24 Incyte Corp Forma sólida amorfa de un inhibidor de proteína bet
DK3472157T3 (da) 2016-06-20 2023-05-01 Incyte Corp Krystallinske faste former af en bet-inhibitor
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE517732C (de) * 1927-10-27 1931-02-09 Then Rudolf Faerbekufe mit einem drehbaren, trommelartigen Rahmen fuer die auf aus-wechselbaren Faerbestoecken aufgehaengten Waren, insbesondere Struempfe
US3194811A (en) * 1963-09-05 1965-07-13 Merck & Co Inc Aroyl-benzindolyl acids
BE755270A (fr) * 1969-08-27 1971-02-25 Sandoz Sa Nouveaux derives du benzo(cd)indole, leur preparation et medicaments contenant ces derives
BE757879A (fr) * 1969-10-24 1971-04-22 Sandoz Sa Derives du benzo(cd)indole, leur preparation et medicaments contenant ces derives
FI206974A (ko) * 1973-07-16 1975-01-17 Sandoz Ag
US4110339A (en) * 1977-11-25 1978-08-29 Eli Lilly And Company 4-(Di-n-propyl)amino-1,3,4,5-tetrahydrobenz[cd]indole
ZA795239B (en) * 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
US4282240A (en) * 1979-11-23 1981-08-04 Merck & Co., Inc. Amino substituted tetrahydrobenzindoles
FR2510111A1 (fr) * 1981-07-24 1983-01-28 Roussel Uclaf Nouveaux derives du piperidin-3-yl indole, leurs sels, leur procede de preparation, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
FR2522658A1 (fr) * 1982-03-05 1983-09-09 Roussel Uclaf Application a titre de medicaments de derives du trans 4-amino benz (c,d) indol-5-ol ainsi que de leurs sels, compositions les renfermant, nouveaux derives et leur procede de preparation
DE3346573A1 (de) * 1983-12-23 1985-07-04 Troponwerke GmbH & Co KG, 5000 Köln 1,3,4,5-tetrahydrobenz(c,d)indole, ein verfahren zu ihrer herstellung und ihre verwendung
US4983622A (en) * 1984-02-06 1991-01-08 Eli Lilly And Company 6-substituted-4-dialkylaminotetrahydrobenz(c,d)indoles
IL74222A (en) * 1984-02-06 1988-07-31 Lilly Co Eli 6-substituted-4-dialkylamino tetrahydrobenz(c,d)indoles,their preparation and pharmaceutical compositions comprising them
US4576959A (en) * 1984-02-06 1986-03-18 Eli Lilly And Company 6-Substituted-4-dialkylaminotetrahydrobenz[c,d]indoles
CA1266482A1 (en) * 1984-05-24 1990-03-06 Carl Kaiser 6-oxygenated-1,3,4,5-tetrahydrobenz(cd)indol-4-amines
DE3525564A1 (de) * 1985-07-15 1987-02-05 Schering Ag Tricyclische verbindungen mit indolstruktur, verfahren zu ihrer herstellung und deren verwendung als arzneimittel
US4745126A (en) * 1987-03-12 1988-05-17 Eli Lilly And Company Method of treating anxiety with tetrahydrobenz[c,d]indole-6-carboxamides
DE3809155A1 (de) * 1988-03-18 1989-09-28 Bayer Ag 1,3,4,5-tetrahydrobenz-(c,d)-indole
SE8901889D0 (sv) * 1989-05-26 1989-05-26 Astra Ab Novel 8-substituted-2-aminotetralines
US5244911A (en) * 1991-03-28 1993-09-14 Eli Lilly And Company 6-heterocyclic-4-amino-1,2,2a,3,4,5-hexahydrobenz(cd)indoles and pharmaceutical use thereof

Also Published As

Publication number Publication date
FI921347A (fi) 1992-09-29
DK0506363T3 (da) 1999-11-08
FI921347A0 (fi) 1992-03-27
JPH0597849A (ja) 1993-04-20
RU2059621C1 (ru) 1996-05-10
DE69229197T2 (de) 1999-10-14
CN1066072A (zh) 1992-11-11
DE69229197D1 (de) 1999-06-24
US5244912A (en) 1993-09-14
AU649319B2 (en) 1994-05-19
NO921128L (no) 1992-09-29
EP0506363A1 (en) 1992-09-30
CN1059210C (zh) 2000-12-06
EP0506363B1 (en) 1999-05-19
HUT62878A (en) 1993-06-28
ATE180256T1 (de) 1999-06-15
HU9201015D0 (en) 1992-06-29
CA2064384A1 (en) 1992-09-29
MX9201374A (es) 1992-10-01
IE921001A1 (en) 1992-10-07
JP3159766B2 (ja) 2001-04-23
HK1013824A1 (en) 1999-10-15
IL101324A (en) 1996-07-23
CN1268352A (zh) 2000-10-04
MY108450A (en) 1996-09-30
CS85692A3 (en) 1992-10-14
NO921128D0 (no) 1992-03-23
IL101324A0 (en) 1992-11-15
NZ242088A (en) 1994-09-27
ZA922070B (en) 1993-09-20
AU1382692A (en) 1992-10-01
NO301642B1 (no) 1997-11-24
GR3030760T3 (en) 1999-11-30
BR9201089A (pt) 1992-11-24
KR100221158B1 (ko) 1999-09-15
YU31492A (sh) 1994-09-09
ES2133303T3 (es) 1999-09-16
HU217590B (hu) 2000-02-28

Similar Documents

Publication Publication Date Title
KR920018043A (ko) 6-헤테로사이클릭-4-아미노-1,3,4,5-테트라하이드로벤즈[cd]인돌
KR930017904A (ko) 축합 이미다조피리딘 유도체
DE69331010D1 (de) Benzoxazol- und benzothiazol-derivate als arzneimittel
KR940005617A (ko) 안지오텐신 ii길항 물질
KR890005095A (ko) 신규 화합물들
PE20030746A1 (es) DERIVADOS DE PIRIDO [2,1-a] ISOQUINOLINA
DE69021472D1 (de) Pyrazolderivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammenstellung.
KR920018042A (ko) 6-헤테로사이클릭-4-아미노-1,2,2a,3,4,5-헥사하이드로벤즈[cd]인돌
KR930701434A (ko) 옥사졸리딘 디온 유도체
KR890017248A (ko) 종양억제제인 방향족 및 헤테로사이클릭 카복스아미드 유도체
SG45259A1 (en) New thiazolybenzofuran derivatives processes for the preparation thereof and pharmaceutical composition comprising the same
KR900016196A (ko) 테트라하이드로벤즈[c, d]인돌 세로토닌 효능제
FI880182A (fi) Foerfarande foer framstaellning av nya tricykliska bensimidazoler.
KR940006584A (ko) 멀미 및 구토 치료용 6-헤데로시클릭-4-아미노-1,3,4,5-테트라하이드로벤즈[cd]인돌
BG100747A (en) INDOLE DERIVATIVES AS 5-HT1 agonists
PE20020083A1 (es) DERIVADOS DE DIPIRIDO[[3,2-b:2',3'-e][1,4] DIAZEPIN-6-ONA COMO INHIBIDORES DE LA TRANSCRIPTASA INVERSA
CA2430124A1 (en) Lactam compounds and pharmaceutical use thereof
KR950000146A (ko) 테트라하이드로벤즈[cd]인돌-6-카복스아미드를 사용한 구토 예방 및 성기능부전의 치료방법
TR200000589T2 (tr) Tümöre karşı maddeler olarak 4-amino -2(5H)-furanonların ve 4-amino-2(5H)-tiyofenonların üreido ve tiyoüreido türevleri.
ATE106868T1 (de) N-((2-oxopyrrolidin-1-yl)acetyl>piperazin- derivate und arzneimittel gegen senile dementia.
HUT59124A (en) Process for producing 2-(aminoalkyl)-5-(arylalkyl)-1,3-dioxane derivatives and pharmaceutical compositions comprising such derivatives as active ingredient
KR910021374A (ko) 헥사하이드로 벤즈[cd]인돌
KR930006024A (ko) 이미다조 인돌리진 유도체 및 그의 제조방법
KR890009888A (ko) 헤테로시클릭 옥소프탈라지닐 아세트산
KR900018054A (ko) 헤테로사이클릭구아니딘 5ht₃길항물질

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20020419

Year of fee payment: 4

LAPS Lapse due to unpaid annual fee